|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INTS12 |
Gene summary for INTS12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INTS12 | Gene ID | 57117 |
| Gene name | integrator complex subunit 12 | |
| Gene Alias | INT12 | |
| Cytomap | 4q24 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024RDK4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57117 | INTS12 | LZE4T | Human | Esophagus | ESCC | 5.45e-11 | 2.75e-01 | 0.0811 |
| 57117 | INTS12 | LZE8T | Human | Esophagus | ESCC | 7.12e-03 | 1.47e-01 | 0.067 |
| 57117 | INTS12 | LZE22T | Human | Esophagus | ESCC | 3.92e-03 | 1.80e-01 | 0.068 |
| 57117 | INTS12 | LZE24T | Human | Esophagus | ESCC | 3.23e-12 | 2.16e-01 | 0.0596 |
| 57117 | INTS12 | LZE6T | Human | Esophagus | ESCC | 4.96e-05 | 1.45e-01 | 0.0845 |
| 57117 | INTS12 | P1T-E | Human | Esophagus | ESCC | 3.02e-04 | 2.88e-01 | 0.0875 |
| 57117 | INTS12 | P2T-E | Human | Esophagus | ESCC | 8.30e-28 | 4.54e-01 | 0.1177 |
| 57117 | INTS12 | P4T-E | Human | Esophagus | ESCC | 3.35e-25 | 5.42e-01 | 0.1323 |
| 57117 | INTS12 | P5T-E | Human | Esophagus | ESCC | 1.19e-09 | 1.82e-01 | 0.1327 |
| 57117 | INTS12 | P8T-E | Human | Esophagus | ESCC | 2.55e-15 | 1.92e-01 | 0.0889 |
| 57117 | INTS12 | P9T-E | Human | Esophagus | ESCC | 4.78e-07 | 1.20e-01 | 0.1131 |
| 57117 | INTS12 | P10T-E | Human | Esophagus | ESCC | 1.87e-18 | 2.35e-01 | 0.116 |
| 57117 | INTS12 | P11T-E | Human | Esophagus | ESCC | 1.24e-14 | 3.85e-01 | 0.1426 |
| 57117 | INTS12 | P12T-E | Human | Esophagus | ESCC | 2.80e-19 | 3.37e-01 | 0.1122 |
| 57117 | INTS12 | P15T-E | Human | Esophagus | ESCC | 1.08e-19 | 3.19e-01 | 0.1149 |
| 57117 | INTS12 | P16T-E | Human | Esophagus | ESCC | 8.65e-16 | 3.53e-01 | 0.1153 |
| 57117 | INTS12 | P17T-E | Human | Esophagus | ESCC | 1.77e-10 | 3.30e-01 | 0.1278 |
| 57117 | INTS12 | P19T-E | Human | Esophagus | ESCC | 5.25e-05 | 2.40e-01 | 0.1662 |
| 57117 | INTS12 | P20T-E | Human | Esophagus | ESCC | 6.45e-20 | 3.26e-01 | 0.1124 |
| 57117 | INTS12 | P21T-E | Human | Esophagus | ESCC | 5.88e-12 | 2.90e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:00311232 | Oral cavity | OSCC | RNA 3'-end processing | 75/7305 | 116/18723 | 1.93e-08 | 3.79e-07 | 75 |
| GO:00344708 | Prostate | BPH | ncRNA processing | 84/3107 | 395/18723 | 8.44e-03 | 3.64e-02 | 84 |
| GO:003447013 | Prostate | Tumor | ncRNA processing | 94/3246 | 395/18723 | 6.02e-04 | 4.31e-03 | 94 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| INTS12 | SNV | Missense_Mutation | c.851C>G | p.Ser284Trp | p.S284W | Q96CB8 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| INTS12 | SNV | Missense_Mutation | novel | c.122N>A | p.Arg41Gln | p.R41Q | Q96CB8 | protein_coding | tolerated(0.32) | benign(0.401) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| INTS12 | SNV | Missense_Mutation | c.507N>A | p.Met169Ile | p.M169I | Q96CB8 | protein_coding | deleterious(0.03) | benign(0.005) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | ||
| INTS12 | SNV | Missense_Mutation | c.1168C>T | p.Pro390Ser | p.P390S | Q96CB8 | protein_coding | tolerated_low_confidence(0.06) | benign(0.236) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| INTS12 | SNV | Missense_Mutation | c.328N>A | p.Glu110Lys | p.E110K | Q96CB8 | protein_coding | tolerated(0.07) | benign(0.005) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD | |
| INTS12 | insertion | Nonsense_Mutation | novel | c.332_333insCTTTTAAATCTGTTATGTTGTAAC | p.Gly111_Val112insPheTerIleCysTyrValValThr | p.G111_V112insF*ICYVVT | Q96CB8 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | ||
| INTS12 | insertion | Frame_Shift_Ins | novel | c.191_192insA | p.Asn64LysfsTer5 | p.N64Kfs*5 | Q96CB8 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| INTS12 | SNV | Missense_Mutation | c.804N>T | p.Lys268Asn | p.K268N | Q96CB8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| INTS12 | SNV | Missense_Mutation | novel | c.1000N>G | p.Thr334Ala | p.T334A | Q96CB8 | protein_coding | deleterious_low_confidence(0.04) | benign(0.058) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| INTS12 | SNV | Missense_Mutation | novel | c.1123C>T | p.Arg375Cys | p.R375C | Q96CB8 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.513) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |